Physician profile
Bella Kushnir
NPI 1770743320
$30,181.99
in general payments reported to CMS, 2019-2025
34 companies · $7,369 in 2025
The $7,369 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $2,630 · 2021: $5,753 · 2022: $4,647 · 2023: $1,270 · 2024: $6,923 · 2025: $7,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,625.00 |
| Food and Beverage | $3,937.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,900.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,230.15 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $867.93 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $743.82 | 2019-2025 | Otezla, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $414.49 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $387.87 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Pfizer INC. | $373.46 | 2019-2025 | |
| Amarin Pharma, INC. | $339.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $336.52 | 2019-2021 | |
| Lilly USA, LLC | $314.28 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Ardelyx, INC. | $289.39 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $277.38 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Janssen Pharmaceuticals, INC | $210.42 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $187.26 | 2019-2025 | Camzyos, Eliquis |
| Aimmune Therapeutics, INC. | $150.43 | 2025 | Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $146.18 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.45 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $125.77 | 2019-2021 | |
| Shield Therapeutics INC | $113.84 | 2023-2024 | Accrufer |
| Axsome Therapeutics, INC. | $70.85 | 2025 | Symbravo |
| Astellas Pharma US INC | $66.48 | 2023 | Veozah, Myrbetriq |
| Allergan, INC. | $64.50 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $64.44 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $50.42 | 2024 | Korlym |
| Vistapharm, INC. | $49.82 | 2021 | |
| Myriad Genetic Laboratories, INC. | $48.88 | 2021 | |
| Exact Sciences Corporation | $41.25 | 2023-2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $39.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $38.49 | 2019-2021 | |
| Intra-Sana Laboratories | $23.16 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Esperion Therapeutics, INC. | $20.83 | 2024 | Nexletol |
| Glycomark, INC. | $20.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2024 | Zoryve |
| Horizon Therapeutics Plc | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Kushnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.